J&J's plaque psoriasis drug wins FDA nod | FDA panel unanimously recommends Mylan's breast cancer generic | Keytruda, Opdivo and Yervoy labels may include additional eye disorders
July 14, 2017
Bio SmartBrief
SIGN UP ⋅   FORWARD
Today's Top Story
J&J's plaque psoriasis drug wins FDA nod
Johnson & Johnson unit Janssen Biotech's Tremfya, or guselkumab, has been granted approval by the FDA as a treatment for adult patients with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
Seeking Alpha (free registration) (7/13) 
LinkedIn Twitter Facebook Google+ Email
Health Care & Policy
FDA panel unanimously recommends Mylan's breast cancer generic
Mylan's trastuzumab, a generic version of Roche Holding's Herceptin indicated for treatment of breast cancer, has been unanimously recommended for approval by an FDA advisory committee. Regulatory authorities in Europe, Australia and Canada are also reviewing the drug.
Seeking Alpha (free registration) (7/13) 
LinkedIn Twitter Facebook Google+ Email
Keytruda, Opdivo and Yervoy labels may include additional eye disorders
The FDA is considering changing labeling information on Yervoy, or ipilimumab; Opdivo, or nivolumab; and Keytruda, or pembrolizumab; to include additional ocular inflammatory conditions.
Regulatory Focus (7/12) 
LinkedIn Twitter Facebook Google+ Email
Kyprolis' survival benefit in multiple myeloma validated in late-stage results
Amgen's late-stage study to evaluate Kyprolis, or carfilzomib, in combination with lenalidomide and dexamethasone as a treatment for patients with relapsed multiple myeloma met its primary endpoint, extending survival by 7.9 months. Participants receiving Kyprolis experienced a decrease of 21% in mortality risk compared with patients treated only with lenalidomide and dexamethasone.
Seeking Alpha (free registration) (7/12) 
LinkedIn Twitter Facebook Google+ Email
FDA fast-tracks Sangamo's drugs for mucopolysaccharidosis type I, II patients
Two in-vivo gene-editing product candidates from Sangamo Therapeutics -- SB-318, intended to treat patients with mucopolysaccharidosis type I and SB-913, for the treatment of MPS II -- have been granted fast-track designations by the FDA. The company is recruiting patients for Phase I/II studies.
Seeking Alpha (free registration) (7/13) 
LinkedIn Twitter Facebook Google+ Email
House subpanel weighs bills on medical product communication
The House Energy and Commerce Health Subcommittee held a hearing on draft bills that would provide clarification on the information that can be included by medical device and drug makers in pre-FDA approval product communication and govern the discussion of off-label use. Subcommittee Chairman Rep. Michael Burgess, R-Texas, said the measures would provide "a targeted approach to addressing the problems presented by our outdated regulatory framework for medical product communication."
Bloomberg BNA (free content) (7/13) 
LinkedIn Twitter Facebook Google+ Email
Germany applies to host EMA post-Brexit
Germany said it will apply to have Bonn become host of the London-based European Medicines Agency following Brexit, adding that the city has "concentrated expertise and strong national partners [the EMA] can rely on." Germany joins the Netherlands, Spain, France, Finland and Denmark in competing to be the home of the EMA once Britain exits the European Union in 2019.
The Express Tribune (Pakistan) (7/12) 
LinkedIn Twitter Facebook Google+ Email
Company & Financial News
Amicus, Alder, Arena raise total of $525M in follow-on offerings
Follow-on offerings raised a total of $525 million for Amicus Therapeutics, Alder BioPharmaceuticals and Arena Pharmaceuticals. Amicus is on its way to submit a new-drug application for Fabry's disease drug migalastat, while Arena's pulmonary arterial hypertension drug ralinepag has met its primary endpoint in a midstage study.
BioCentury (7/13) 
LinkedIn Twitter Facebook Google+ Email
The Latest From BIO ...
Become an advocate for biotechnology
Learn more about key policy issues affecting biotechnology in Washington, D.C., and state capitals around the country. With the unpredictability of the federal level coupled with the increasingly hostile state legislatures, it is vital that the biotechnology industry amplify its voice on the federal, state and local levels. Become an advocate for biotechnology by joining BIO Action today. Now, more than ever, we need your voice! Text BIO to 52886 or visit BIO's website.
LinkedIn Twitter Facebook Google+ Email
Learn more about BIO:
Conferences | Join Bio | Media | Issues | Industry
Food & Agriculture
BIO, industry groups call for revisions of "outdated" biotech crop regulations
BIO and other industry groups urged the USDA to revise a number of provisions proposed by the Animal and Plant Health Inspection Service, which assess biotech organisms to identify if they pose plant pest or noxious weed risks. BIO said APHIS' proposed ruling "would create two parallel regulatory systems to evaluate the same risk, under the same statutory authority, in potentially inconsistent ways."
The National Law Review (7/14) 
LinkedIn Twitter Facebook Google+ Email
Industrial & Environmental
Researchers develop ways to cut cost of biofuels, ethanol, gasoline
Scientists from Rutgers University-New Brunswick and Michigan State University have developed ways to genetically engineer enzyme surfaces that bind less to cornstalks and other cellulosic biomass, which lowers enzyme costs in biofuels production. "The challenge is breaking down cellulose [plant] material, using enzymes, into sugars that can be fermented into ethanol," said researcher Shishir P. S. Chundawat.
Ethanol Producer Magazine online (7/13) 
LinkedIn Twitter Facebook Google+ Email
News From BIO
Registration for BIO 2017 World Congress now open
The Biotechnology Innovation Organization (BIO) announced registration and housing are now open for the 2017 World Congress on Industrial Biotechnology. The conference will be held July 23-26, 2017, at the Palais des congres de Montreal in Montreal. Register now.
LinkedIn Twitter Facebook Google+ Email
Learn more about BIO:
Conferences | Join Bio | Media | Issues | Industry
  
  
I am tomorrow, or some future day, what I establish today. I am today what I established yesterday -- or some previous day.
Harvey Spencer Lewis,
writer
LinkedIn Twitter Facebook Google+ Email
  
  
The news summaries appearing in BIO SmartBrief are based on original information from news organizations and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The information is not compiled or summarized by BIO. Questions and comments should be directed to SmartBrief at bio@smartbrief.com.
Sign Up
SmartBrief offers 200+ newsletters
Advertise
Learn more about the SmartBrief audience
Subscriber Tools:
Contact Us:
Advertising  -  Wynn Hansen
P: 202.470.1149
Editor  -  Tara Rosenzweig
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2017 SmartBrief, Inc.®
Privacy policy |  Legal Information